JAK2 Inactivating Mutations Promotes Endometrial Cancer Progression by Targeting HIF-1α

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 25

PMID 39720955

Authors

Zheng Chen

Xuan Zheng

Weijian Zeng

Juan Wang

Qin Lin

Affiliations

Soon will be listed here.

Abstract

Objective: Endometrial cancer (EC) is the ninth most common malignancy among women. While mutations in JAK2 are frequently observed in EC, the specific biological functions of JAK2 in endometrial cancer are poorly understood.

Methods: The genetic alterations of JAK2 in different cancer types were explored using sequencing dataset deposited at TCGA database. JAK2 mutations were detected in EC formalin-fixed paraffin-embedded (FFPE) samples using Sanger sequencing. The expression levels of JAK2 was accessed using the TCGA database and immunohistochemistry. Furthermore, the relationships between JAK2 expression and staging and prognosis of EC patients were investigated using the TCGA database. Down-regulation of JAK2 were achieved by transient transfection with short hairpin RNAs (shRNAs). Effects of JAK2 on cancer cells proliferation and migration were evaluated by CCK8, colony formation, and transwell assay. The potential biological functions of JAK2 in EC were identified based on bioinformatics analysis. Effects of JAK2 on expression levels of target genes were detected by RT-qPCR and western blotting. Co-immunoprecipitation (co-IP) assays was used to detect the physical association between JAK2 and HIF-1α.

Results: Frequent mutations and down-regulation of JAK2 were found in EC. Loss-of-function (LOF) assays suggested that JAK2 silencing in endometrial cancer cells promoted cell proliferation and migration, which were partially dependent on HIF-1α signaling pathway. Furthermore, our findings demonstrated that JAK2 interacted with HIF-1α and reduced HIF1α protein expression under hypoxia.

Conclusion: These findings revealed novel molecular mechanisms underlying JAK2 LOF mutations-driven endometrial tumorigenesis and revealed that the HIF-1α pathway may be a potential therapeutic target in JAK2-mutated endometrial cancer.

References

Berenson J, To J, Spektor T, Martinez D, Turner C, Sanchez A . A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2020; 26(10):2346-2353. DOI: 10.1158/1078-0432.CCR-19-1899. View

Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li C, Salvo M . Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018; 36(4):683-695. PMC: 6752723. DOI: 10.1007/s10637-018-0580-2. View

Chen M, Zeng J, Chen S, Li J, Wu H, Dong X . SPTBN1 suppresses the progression of epithelial ovarian cancer via SOCS3-mediated blockade of the JAK/STAT3 signaling pathway. Aging (Albany NY). 2020; 12(11):10896-10911. PMC: 7346039. DOI: 10.18632/aging.103303. View

Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N . Ruxolitinib. Recent Results Cancer Res. 2018; 212:119-132. DOI: 10.1007/978-3-319-91439-8_6. View

Thomas S, Snowden J, Zeidler M, Danson S . The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015; 113(3):365-71. PMC: 4522639. DOI: 10.1038/bjc.2015.233. View

Zhao F, Qin C . EGF promotes HIF-1α expression in colorectal cancer cells and tumor metastasis by regulating phosphorylation of STAT3. Eur Rev Med Pharmacol Sci. 2019; 23(3):1055-1062. DOI: 10.26355/eurrev_201902_16993. View

May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E . Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer. Oncogene. 2004; 24(6):1011-20. DOI: 10.1038/sj.onc.1208325. View

Lin Q, Chen Z, Shi W, Lv Z, Wan X, Gao K . JAK1 inactivation promotes proliferation and migration of endometrial cancer cells via upregulating the hypoxia-inducible factor signaling pathway. Cell Commun Signal. 2022; 20(1):177. PMC: 9661757. DOI: 10.1186/s12964-022-00990-5. View

Parra-Izquierdo I, Castanos-Mollor I, Lopez J, Gomez C, San Roman J, Sanchez Crespo M . Lipopolysaccharide and interferon-γ team up to activate HIF-1α via STAT1 in normoxia and exhibit sex differences in human aortic valve interstitial cells. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(9):2168-2179. DOI: 10.1016/j.bbadis.2019.04.014. View

10.

Fogelman D, Cubillo A, Garcia-Alfonso P, Limon Miron M, Nemunaitis J, Flora D . Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer. Cancer Med. 2018; 7(11):5382-5393. PMC: 6246927. DOI: 10.1002/cam4.1703. View

11.

Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C . Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014; 123(9):1372-83. DOI: 10.1182/blood-2013-05-504555. View

12.

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

13.

Yuan K, Ye J, Liu Z, Ren Y, He W, Xu J . Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression. J Exp Clin Cancer Res. 2020; 39(1):9. PMC: 6956509. DOI: 10.1186/s13046-019-1514-3. View

14.

Kane L, Lazarou M, Fogel A, Li Y, Yamano K, Sarraf S . PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity. J Cell Biol. 2014; 205(2):143-53. PMC: 4003245. DOI: 10.1083/jcb.201402104. View

15.

Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S . Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005; 24(36):5552-60. DOI: 10.1038/sj.onc.1208719. View

16.

Fan X, Fu H, Xie N, Guo H, Fu T, Shan Y . Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer. Aging (Albany NY). 2021; 13(19):22830-22842. PMC: 8544303. DOI: 10.18632/aging.203575. View

17.

Li Y, Wei J, Sun Y, Zhou W, Ma X, Guo J . Regulates the Proliferation, Migration, Invasion, and Cell Cycle of Breast Cancer Cells via the JAK2/STAT3 Signaling Axis. Int J Mol Sci. 2023; 24(21). PMC: 10647495. DOI: 10.3390/ijms242115819. View

18.

Percy M, McMullin M . The V617F JAK2 mutation and the myeloproliferative disorders. Hematol Oncol. 2005; 23(3-4):91-3. DOI: 10.1002/hon.761. View

19.

Zhao Y, Xing C, Deng Y, Ye C, Peng H . HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 2023; 11(1):234-251. PMC: 10425810. DOI: 10.1016/j.gendis.2023.02.039. View

20.

Xia C, Dong X, Li H, Cao M, Sun D, He S . Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022; 135(5):584-590. PMC: 8920425. DOI: 10.1097/CM9.0000000000002108. View